Anti-BCMA CAR-NK Cell Therapy (Sichuan Kelun-Biotech) |
|
Phase 1 Clinical |
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
Anti-BCMA/CD19 CAR-T(Autolus) |
|
Phase 1 Clinical |
|
Multiple Myeloma |
Details
|
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics |
Multiple Myeloma |
Details
|
P-BCMA-101 |
P-BCMA-101 |
Phase 2 Clinical |
Poseida Therapeutics |
Multiple Myeloma |
Details
|
LCAR-B4822M |
LCAR-B4822M |
Phase 1 Clinical |
Genscript Biotech Corp |
Multiple Myeloma |
Details
|
Anti BCMA CART cell therapy (Shanghai YaKe Biotechnology) |
|
Phase 1 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
MCM-998 |
MCM-998; LXG-250 |
Phase 1 Clinical |
Novartis Pharma Ag |
Multiple Myeloma |
Details
|
KITE-585 |
KITE-585 |
Phase 1 Clinical |
Kite Pharma, National Cancer Institute |
Multiple Myeloma |
Details
|
BCMA CAR-T Cells (Pregene) |
PRG-1801 |
Phase 1 Clinical |
Shenzhen Prekin Biopharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University |
Multiple Myeloma |
Details
|
BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology) |
CBG-002 CAR-T |
Phase 1 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) |
|
Phase 3 Clinical |
The First Affiliated Hospital Of Soochow University |
Multiple Myeloma |
Details
|
Anti-BCMA CAR-T cell therapy (Xinqiao Hospital) |
|
Phase 1 Clinical |
|
Multiple Myeloma |
Details
|
SEA-BCMA |
SEA-BCMA; SGN-BCMA |
Phase 1 Clinical |
Seattle Genetics |
Multiple Myeloma |
Details
|
PBCAR-269A |
PBCAR-269A |
Phase 2 Clinical |
Precision Biosciences |
Multiple Myeloma |
Details
|
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) |
|
Phase 1 Clinical |
Shengyan Pharmaceutical Technology |
Multiple Myeloma |
Details
|
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) |
|
Phase 1 Clinical |
Sichuan University |
Multiple Myeloma |
Details
|
HBI-0101 |
HBI-0101 |
Phase 1 Clinical |
Hadassah Medical Organization |
|
Details
|
lentiviral transfected chimeric antigen receptor T-cells(Icell Gene) |
|
|
Icell Gene Therapeutics |
|
Details
|
C-CAR088 |
C-CAR088 |
Phase 1 Clinical |
Cellular Biomedicine (Shanghai) Co Ltd |
Multiple Myeloma |
Details
|
CC-99712 |
CC-99712 |
Phase 1 Clinical |
Celgene Corp |
Multiple Myeloma |
Details
|
MEDI-2228 |
MEDI-2228 |
Phase 1 Clinical |
Medimmune Llc |
Multiple Myeloma |
Details
|
CC-98633 |
CC-98633 |
Phase 1 Clinical |
Celgene Corp |
Multiple Myeloma |
Details
|
BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) |
|
Phase 2 Clinical |
Asclepius Technology Company Group |
Multiple Myeloma |
Details
|
Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology) |
|
Clinical |
Wuhan Bio-Raid Biotechnology |
Hematologic Neoplasms |
Details
|
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics |
Multiple Myeloma |
Details
|
ACTR 087/SEA BCMA combination therapy |
|
Phase 1 Clinical |
Unum Therapeutics |
Multiple Myeloma |
Details
|
BCMA-UCART cell therapy (Shanghai Bioray Laboratory) |
|
|
Bioray Laboraytories Inc |
|
Details
|
GC-012F |
GC-012F |
Phase 1 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Multiple Myeloma |
Details
|
JWCAR129 |
JWCAR129; JWCAR-129 |
Phase 1 Clinical |
Suzhou Yaomingjunuo Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech) |
LCAR-BCX |
Phase 1 Clinical |
Nanjing Legend Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
BCMA CAR-T cell therapy (Hebei Senlang Biotechnology) |
|
Clinical |
Hebei Senlang Biological Technology Co Ltd |
Multiple Myeloma |
Details
|
Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) |
|
Phase 1 Clinical |
Persongen Biotherapeutics |
Multiple Myeloma |
Details
|
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) |
|
Phase 1 Clinical |
The First Affiliated Hospital Of Nanchang University |
Multiple Myeloma |
Details
|
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) |
|
Clinical |
Huazhong University Of Science And Technology |
Multiple Myeloma |
Details
|
Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) |
|
Phase 2 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian) |
Descartes-08 |
Phase 2 Clinical |
Cartesian Therapeutics |
Myasthenia Gravis; Multiple Myeloma |
Details
|
Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) |
|
Phase 1 Clinical |
Hrain Biotechnology |
POEMS Syndrome |
Details
|
Anti-BCMA CAR T-cell therapy (Arcellx) |
CART-ddBCMA |
Phase 1 Clinical |
Arcellx |
Multiple Myeloma |
Details
|
BCMA CAR-T cell therapy (Chongqing Precision Biotech) |
|
Phase 2 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Plasmacytoma; Multiple Myeloma; Neoplasms, Plasma Cell |
Details
|
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) |
BCMA-CART |
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
CTX-120 |
CTX-120 |
Phase 1 Clinical |
Crispr Therapeutics |
Multiple Myeloma |
Details
|
Pacanalotamab |
AMG-420; BI-836909 |
Phase 1 Clinical |
Micromet |
Multiple Myeloma |
Details
|
ALLO-605 |
ALLO-605; ALLO605 |
Phase 2 Clinical |
Allogene Therapeutics Inc |
Multiple Myeloma |
Details
|
ALLO-715 |
ALLO-715 |
Phase 1 Clinical |
Allogene Therapeutics Inc, Cellectis |
Multiple Myeloma |
Details
|
BCMA CAR-T Cell Therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Multiple Myeloma |
Details
|
AMG-224 |
AMG-224 |
Phase 1 Clinical |
Amgen Inc |
Multiple Myeloma |
Details
|
EMB-06(Shanghai Epimab Biotherapeutics) |
EMB-06; EMB06 |
Phase 2 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Multiple Myeloma |
Details
|
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) |
|
Phase 2 Clinical |
People'S Liberation Army General Hospital Military Service |
Multiple Myeloma |
Details
|
Alnuctamab |
CC-93269; EM-901 |
Phase 1 Clinical |
Celgene Corp |
Multiple Myeloma |
Details
|
CM-336(Connaught Biomedical Technology) |
CM-336 |
Phase 1 Clinical |
Keymed Biosciences Co Ltd |
Multiple Myeloma |
Details
|
REGN-5459 |
REGN-5459 |
Phase 2 Clinical |
Regeneron Pharmaceuticals Inc |
Multiple Myeloma; Renal Insufficiency, Chronic |
Details
|
Orvacabtagene autoleucel |
ET-140; FCARH-143; ET140-CAR; MCARH-171; JCARH-125 |
Phase 2 Clinical |
Juno Therapeutics |
Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
PHE-885 |
PHE-885 |
Phase 2 Clinical |
Novartis Pharma Ag |
Hematologic Neoplasms; Multiple Myeloma |
Details
|
GR-1803 |
GR-1803 |
Phase 1 Clinical |
Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd |
Multiple Myeloma |
Details
|
BCMA-NKE |
BCMA-NKE |
Phase 1 Clinical |
Bristol-Myers Squibb Company |
Multiple Myeloma |
Details
|
Zevorcabtagene Autoleucel |
CT-053-CARsgen |
Phase 2 Clinical |
Carsgen Biomedicine (Shanghai) Co Ltd |
Multiple Myeloma |
Details
|
bb-21217 |
bb-21217 |
Phase 1 Clinical |
Bristol-Myers Squibb Company, Bluebird Bio |
Multiple Myeloma |
Details
|
TNB-383B |
TNB-383B; ABBV-383 |
Phase 1 Clinical |
Teneobio, Abbvie Inc |
Multiple Myeloma |
Details
|
BCMA TriTAC |
HPN-217 |
Phase 2 Clinical |
Harpoon Therapeutics, Abbvie Inc |
Multiple Myeloma |
Details
|
Human BCMA chimeric antigen receptor autologous T cell(Nanjing Reindeer Medical Technology) |
CT-103A; CT103A; IBI-326 |
Phase 3 Clinical |
Innovent Biologics(Suzhou) Co Ltd, Nanjing Iaso Biotherapeutics Co Ltd |
Multiple Myeloma; Neuromyelitis Optica |
Details
|
Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) |
|
Phase 1 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
Pavurutamab |
AMG-701 |
Phase 1 Clinical |
Amgen Inc |
Multiple Myeloma |
Details
|
Elranatamab |
PF-06863135 |
Phase 3 Clinical |
Pfizer Pharmaceuticals Ltd (China) |
Bone Marrow Neoplasms; Multiple Myeloma |
Details
|
Humanized CART Directed Against BCMA |
ARI-0002h |
|
Instituto De Salud Carlos Iii |
|
Details
|
FT-576 |
FT-576 |
Phase 1 Clinical |
University Of Minnesota, Fate Therapeutics Inc |
Bone Marrow Neoplasms; Multiple Myeloma |
Details
|